Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial LANCET Blackshear, J. L., Baker, V. S., Rubino, F., Safford, R., Lane, G., Flipse, T., Malouf, J., Thompson, R., Webel, R., Flaker, G. C., Young, L., Hess, D., Friedman, G., Burger, R., McAnulty, J. H., Coull, B. M., Marchant, C., Timberg, J., Janzik, C., Giraud, G., Halperin, B., Kron, J., Wynn, M., Raitt, M., Anderson, D. C., Asinger, R. W., Newburg, S. M., Fifield, J., Bundlie, S. R., Koller, R. L., Tarrel, R. D., Dick, C., Haugland, J. M., Jorgensen, C. R., Leonard, A. D., KANTER, M. C., Solomon, D. H., Zabalgoitia, M., Mego, D., Carter, J. E., Boyd, S. Y., Boop, B. S., Lalonde, D., Modlin, R., LOGAN, W. R., Green, B. J., Hamilton, W. P., Mezei, L., RIGGIO, S., Feldman, G., Hayward, A., Strauss, R., ANDERSON, W., Grover, J., McKenzie, M., HartMcArthur, P., Gramberg, M., Houston, H., Halperin, J. L., Rothauf, E. B., Weinberger, J. M., Goldman, M. E., Laupacis, A., Chan, K. L., Bourque, P., Biggs, J., Ives, A., Feinberg, W. M., Kern, K. B., Pennock, G. D., Fenster, P. E., Huerta, B. J., Ohm, J., Dittrich, H. C., Kerridge, C., Keen, W., Swenson, M., Kopecky, S. L., Litin, S. C., Wiebers, D. O., Holland, A. E., Brown, R. D., Khandheria, B. K., Meissner, I., Tucker, K. R., Rothbart, R., Torelli, J., Schmidt, J., Murray, D., RUZICH, R. S., Loutfi, H., Appleton, C., Ingall, T., Carlson, L., Wilson, D., Dunn, M., Nolte, B., Edwards, C., Dick, A., Price, L. A., Janosik, D. L., Bjerregaard, P., Quattromani, A., Schiller, L., Labovitz, A., Burch, C., Parks, B. J., Thompson, D., BERARDUCCI, L., Carey, S., Vigil, A., Falk, R., Battinelli, N., McNeil, M., Davidoff, R., Bernard, S., Bergethon, P., Fiori, L., Albers, G., Atwood, E., Clark, J., Tong, D., Yenari, M., Froelicker, V., Lutsep, H., Hock, N. H., Quaglietti, S., Kemp, S., Alpert, M. A., Rothrock, J. F., Hupp, C. H., Massey, C. V., Hamilton, W. J., Miller, V. T., Fox, J. 1996; 348 (9028): 633-638


Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF). However, this treatment carries a risk of bleeding and the need for frequent medical monitoring. We sought an alternative that would be safer and easier to administer to patients with AF who are at high-risk of thromboembolism.1044 patients with AF and with at least one thromboembolic risk factor (congestive heart failure or left ventricular fractional shortening < or = 25%, previous thromboembolism, systolic blood pressure of more than 160 mm Hg at study enrollment, or being a woman aged over 75 years) were randomly assigned either a combination of low-intensity, fixed-dose warfarin (international normalised ratio [INR] 1.2-1.5 for initial dose adjustment) and aspirin (325 mg/day) or adjusted-dose warfarin (INR 2.0-3.0). Drugs were given open-labelled.The mean INR during follow-up of patients taking combination therapy (n = 521) was 1.3, compared with 2.4 for those taking adjusted-dose warfarin (n = 523). During follow-up, 54% of INRs in patients taking combination therapy were 1.2-1.5 and 34% were less than 1.2. The trial was stopped after a mean, follow-up of 1.1 years when the rate of ischaemic stroke and systemic embolism (primary events) in patients given combination therapy (7.9% per year) was significantly higher than in those given adjusted-dose warfarin (1.9% per year) at an interim analysis (p < 0.0001), an absolute reduction of 6.0% per year (95% Cl 3.4, 8.6) by adjusted-dose warfarin. The annual rates of disabling stroke (5.6% vs 1.7%, p = 0.0007) and of primary event or vascular death (11.8% vs 6.4%, p = 0.002), were also higher with combination therapy. The rates of major bleeding were similar in both treatment groups.Low-intensity, fixed-dose warfarin plus aspirin in this regimen is insufficient for stroke prevention in patients with non-valvular AF at high-risk for thromboembolism; adjusted-dose warfarin (target INR 2.0-3.0) importantly reduces stroke for high-risk patients.

View details for Web of Science ID A1996VF60900007

View details for PubMedID 8782752